- H.R. 10171August 27, 2026
- H.R. 10156August 27, 2026
- H.R. 10172August 27, 2026
- H.R. 10160August 27, 2026
- H.R. 10181August 27, 2026
- H.R. 10176August 27, 2026
- H.Res. 1496August 27, 2026
- H.R. 10164August 27, 2026
- H.R. 10170August 27, 2026
- H.Res. 1494August 27, 2026
- H.R. 10163August 27, 2026
- H.R. 10157August 27, 2026
- Administration
- Agriculture
- Agriculture, Nutrition, And Forestry
- Appropriations
- Armed Services
- Banking, Housing, And Urban Affairs
- Budget
- Commerce, Science, And Transportation
- Education and Workforce
- Energy And Commerce
- Energy And Natural Resources
- Environment And Public Works
- Ethics
- Finance
- Financial Services
- Foreign Affairs
- Foreign Relations
- Health, Education, Labor, And Pensions
- Homeland Security
- Homeland Security And Governmental Affa…
- Indian Affairs
- Indian and Insular Affairs
- Intelligence
- Judiciary
- Natural Resources
- Oversight And Government Reform
- Permanent Select Intelligence
- Rules
- Rules And Administration
- Science, Space, And Technology
- Select Intelligence
- Small Business
- Small Business And Entrepreneurship
- Subcommittee on Aviation
- Subcommittee on Border Security and Enf…
- Subcommittee on Coast Guard and Maritim…
- Subcommittee on Commodity Markets, Digi…
- Subcommittee on Conservation, Research,…
- Subcommittee on Counterterrorism and In…
- Subcommittee on Cybersecurity and Infra…
- Subcommittee on Disability Assistance a…
- Subcommittee on Economic Development, P…
- Subcommittee on Economic Opportunity
- Subcommittee on Emergency Management an…
- Subcommittee on Energy and Mineral Reso…
- Subcommittee on Federal Lands
- Subcommittee on Forestry and Horticultu…
- Subcommittee on General Farm Commoditie…
- Subcommittee on Health
- Subcommittee on Highways and Transit
- Subcommittee on Livestock, Dairy, and P…
- Subcommittee on Nutrition and Foreign A…
- Subcommittee on Oversight and Investiga…
- Subcommittee on Oversight, Investigatio…
- Subcommittee on Railroads, Pipelines, a…
- Subcommittee on Transportation and Mari…
- Subcommittee on Water Resources and Env…
- Subcommittee on Water, Wildlife and Fis…
- Transportation And Infrastructure
- Veterans' Affairs
- Ways And Means

S. 3014
U.S. Senate•In Senate Committee
Summary
S. 3014, the Ensuring Timely Access to Generics Act of 2025, was introduced in the Senate on Oct 16, 2025 by Sen. Jeanne Shaheen (D) with 2 co-sponsors. It was referred to Health, Education, Labor, And Pensions, and last saw action on Oct 16, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Record
Text
S. 3014 has 2 co-sponsors.
sb3014/introduced-in-senate.txt119 S3014 IS: Ensuring Timely Access to Generics Act of 2025U.S. Senate2025-10-16text/xmlENPursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.II119th CONGRESS1st SessionS. 3014IN THE SENATE OF THE UNITED STATESOctober 16, 2025Mrs. Shaheen (for herself and Ms. Collins ) introduced the following bill; which wasread twice and referred to the Committee onHealth, Education, Labor, and PensionsA BILLTo amend the Federal Food, Drug, and Cosmetic Act with respect to citizenpetitions.1.Short titleThis Act may be cited as the Ensuring Timely Access to Generics Act of 2025 .2.Ensuring timely access to genericsSection 505(q) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(q) ) is amended—(1)in paragraph (1)—(A)in subparagraph (A)(i), by inserting , 10.31, after 10.30 ;(B)in subparagraph (E)—(i)by striking application and and inserting application or ;(ii)by striking If the Secretary and inserting the following:(i)In generalIf the Secretary; and(iii)by striking the second sentence and inserting the following:(ii)Primary purpose of delaying(I)In generalIn determining whether a petition was submitted with the primary purpose of delaying an application, the Secretary may consider the following factors:(aa)Whether the petition was submitted in accordance with paragraph (2)(B), based on when the petitioner knew the relevant information relied upon to form the basis of such petition.(bb)When the petition was submitted in relation to when the petitioner reasonably should have known the relevant information relied upon to form the basis of such petition.(cc)Whether the petitioner has submitted multiple or serial petitions or supplements to petitions raising issues that reasonably could have been known to the petitioner at the time of submission of the earlier petition or petitions.(dd)Whether the petition was submitted close in time to a known, first date upon which an application under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act could be approved.(ee)Whether the petition was submitted without relevant data or information in support of the scientific positions forming the basis of such petition.(ff)Whether the petition raises the same or substantially similar issues as a prior petition to which the Secretary has responded substantively already, including if the subsequent submission follows such response from the Secretary closely in time.(gg)Whether the petition requests changing the applicable standards that other applicants are required to meet, including requesting testing, data, or labeling standards that are more onerous or rigorous than the standards the Secretary has determined to be applicable to the listed drug, reference product, or petitioner’s version of the same drug.(hh)The petitioner's record of submitting petitions to the Food and Drug Administration that have been determined by the Secretary to have been submitted with the primary purpose of delay.(ii)Other relevant and appropriate factors, which the Secretary shall describe in guidance.(II)GuidanceThe Secretary may issue or update guidance, as appropriate, to describe factors the Secretary considers in accordance with subclause (I).;(C)by striking subparagraph (F);(D)by redesignating subparagraphs (G) through (I) as subparagraphs (F) through (H), respectively; and(E)in subparagraph (H), as so redesignated, by striking submission of this petition and inserting submission of this document ;(2)in paragraph (2)—(A)by redesignating subparagraphs (A) through (C) as subparagraphs (C) through (E), respectively;(B)by inserting before subparagraph (C), as so redesignated, the following:(A)In generalA person shall submit a petition to the Secretary under paragraph (1) before filing a civil action in which the person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act. Such petition and any supplement to such a petition shall describe all information and arguments that form the basis of the relief requested in any civil action described in the previous sentence.(B)Timely submission of citizen petitionA petition and any supplement to a petition shall be submitted within 180 days after the person knew the information that forms the basis of the request made in the petition or supplement.;(C)in subparagraph (C), as so redesignated—(i)in the heading, by strikingwithin 150 days ;(ii)in clause (i), by striking during the 150-day period referred to in paragraph (1)(F), ; and(iii)by amending clause (ii) to read as follows:(ii)on or after the date that is 151 days after the date of submission of the petition, the Secretary approves or has approved the application that is the subject of the petition without having made such a final decision.;(D)by amending subparagraph (D), as so redesignated, to read as follows:(D)Dismissal of certain civil actions(i)PetitionIf a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (A), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.(ii)TimelinessIf a person files a civil action against the Secretary in which a person seeks to set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act without complying with the requirements of subparagraph (B), the court shall dismiss with prejudice the action for failure to timely file a petition.(iii)Final responseIf a civil action is filed against the Secretary with respect to any issue raised in a petition timely filed under paragraph (1) in which the petitioner requests that the Secretary take any form of action that could, if taken, set aside, delay, rescind, withdraw, or prevent submission, review, or approval of an application submitted under subsection (b)(2) or (j) of this section or section 351(k) of the Public Health Service Act before the Secretary has taken final agency action on the petition within the meaning of subparagraph (C), the court shall dismiss without prejudice the action for failure to exhaust administrative remedies.; and(E)in clause (iii) of subparagraph (E), as so redesignated, by striking as defined under subparagraph (2)(A) and inserting within the meaning of subparagraph (C) ; and(3)in paragraph (4)—(A)by strikingExceptions in the paragraph heading and all that follows through This subsection does and insertingExceptions.— This subsection does ;(B)by striking subparagraph (B); and(C)by redesignating clauses (i) and (ii) as subparagraphs (A) and (B), respectively, and adjusting the margins accordingly.
Tracker
The tracker indicates the progress of this legislation as it moves through the legislative process.
- Introduced2025-10-16
- Passed Senate
- Passed House
- Conference
- To President
- Became Law
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions.
Sponsors
Sen. Jeanne Shaheen (D) sponsors S. 3014, and 2 members have co-sponsored it, 1 of them from the day it was introduced.
Committees
S. 3014 went before 1 committee: Health, Education, Labor, and Pensions.

Actions
S. 3014 has taken 2 actions since Oct 16, 2025.
| Chamber | Action | |||
|---|---|---|---|---|
Oct 16, 2025 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions.Health, Education, Labor, and Pensions Committee | ||
Oct 16, 2025 | — | Introduced in Senate |
Votes
S. 3014 has not gone to a roll call.
Related bills
1 bill is related to S. 3014.
Titles
S. 3014 goes by 3 titles, 1 of them short titles.
- Ensuring Timely Access to Generics Act of 2025 — Display Title
- Ensuring Timely Access to Generics Act of 2025 — Short Title(s) as Introduced
- A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. — Official Title as Introduced
Lobbying
20 clients hired 21 firms and 134 registered lobbyists who named S. 3014 in 30 quarterly filings, 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.
Filed under Medicare/Medicaid, Pharmacy, Health Issues, Copyright/Patent/Trademark, Taxation/Internal Revenue Code, Budget/Appropriations, Trade (domestic/foreign), Small Business.
Clients
Who paid to be heard, by how many filings named the bill.
Firms
Registrants who filed on the bill, by filings.
Lobbyists
Named on the filings that cite the bill. The 20 named most often, of 134.
| Lobbyist | Firms | Clients | Filings |
|---|---|---|---|
| THOMAS GILES | 2 | 2 | 4 |
| ERIK KOMENDANT | 2 | 2 | 3 |
| ALEXANDER PERKINS | 1 | 1 | 2 |
| ALYENE MLINAR | 1 | 1 | 2 |
| ALYSSA PALISI | 1 | 1 | 2 |
| AMANDA INGRAM JACOBS | 1 | 1 | 2 |
| AMANDA SCHWARTZ | 1 | 1 | 2 |
| AMY MODLIN | 1 | 1 | 2 |
| ANNIE WOLF | 1 | 1 | 2 |
| BRUCE MEHLMAN | 1 | 1 | 2 |
| CAITLIN VAN SANT | 1 | 1 | 2 |
| DAVID MERRITT | 1 | 1 | 2 |
| DAVID THOMAS | 1 | 1 | 2 |
| DEAN ROSEN | 1 | 1 | 2 |
| EARL FLOOD | 1 | 1 | 2 |
| ELISE FINLEY PICKERING | 1 | 1 | 2 |
| ERICA CHABOT | 1 | 1 | 2 |
| ERIK HAMES | 1 | 1 | 2 |
| HELEN TOLAR | 1 | 1 | 2 |
| JON ADAME | 1 | 1 | 2 |
Filings
The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.
| Client | Registrant | Period | Reported | Document |
|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 2026 second_quarter | $7.4M | 2nd Quarter - Report |
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) | 2026 second_quarter | $3M | 2nd Quarter - Report |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | BIOTECHNOLOGY INNOVATION ORGANIZATION | 2026 second_quarter | $2.4M | 2nd Quarter - Report |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2026 first_quarter | $1.5M | 1st Quarter - Report |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | BLUE CROSS AND BLUE SHIELD ASSOCIATION | 2026 second_quarter | $990K | 2nd Quarter - Report |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | 2026 second_quarter | $890K | 2nd Quarter - Report |
| KAISER FOUNDATION HEALTH PLAN INC | KAISER FOUNDATION HEALTH PLAN INC. | 2026 second_quarter | $530K | 2nd Quarter - Report |
| BLUE CROSS BLUE SHIELD OF MICHIGAN | BLUE CROSS BLUE SHIELD OF MICHIGAN | 2026 second_quarter | $276.3K | 2nd Quarter - Report |
| BLUE CROSS BLUE SHIELD OF MICHIGAN | BLUE CROSS BLUE SHIELD OF MICHIGAN | 2026 first_quarter | $276.3K | 1st Quarter - Report |
| AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS | 2026 second_quarter | $260K | 2nd Quarter - Report |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 2026 second_quarter | $220K | 2nd Quarter - Report |
| BLUECROSS BLUESHIELD OF TENNESSEE | BLUECROSS BLUESHIELD OF TENNESSEE | 2026 first_quarter | $220K | 1st Quarter - Report |
| BLUECROSS BLUESHIELD OF TENNESSEE | BLUECROSS BLUESHIELD OF TENNESSEE | 2026 second_quarter | $140K | 2nd Quarter - Report |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 2026 first_quarter | $130K | 1st Quarter - Report |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 2026 second_quarter | $90K | 2nd Quarter - Report |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 2026 first_quarter | $90K | 1st Quarter - Report |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. | 2026 second_quarter | $80K | 2nd Quarter - Report |
| AMGEN | THE NICKLES GROUP, LLC | 2026 second_quarter | $60K | 2nd Quarter - Report |
| ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA) | FIERCE GOVERNMENT RELATIONS | 2026 second_quarter | $60K | 2nd Quarter - Report |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 2026 second_quarter | $50K | 2nd Quarter - Termina… |
Classification
The Congressional Research Service files S. 3014 under Health, one of its 31 policy areas.
CRS Subjects
CRS assigns every bill one policy area from its 31; S. 3014’s is Health.
s3014/policy-areas.txtSource: congress.gov · legiscan.com